BCL9L and colorectal carcinoma: In contrast, a report from Xicola et al. [45] used WES in early-onset CRCs to demonstrate that African American patients had reduced TMB, CNV and mutation frequencies in APC and other known CRC driver genes compared to Caucasians but harbored loss-of-function mutations in BCL9L, a negative regulator of B-catenin.